Nesiritide in perspective: Evolving approaches to the management of acute decompensated heart failure

Drugs of Today

Volumn 39, Issue 10, 2003, Pages 767-774

  Mills, Roger M ^a   Hobbs, Robert E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; NESIRITIDE;

ACUTE HEART FAILURE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; REVIEW;

ACUTE DISEASE; ANIMALS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0344628835     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.10.799470     Document Type: Review

References (26)

1. Hobbs, R.E., Mills, R.M., Young, J.B. An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 2001, 10: 935-42.
2. Burger, M.R., Burger, A.J. BNP in decompensated heart failure: Diagnostic, prognostic and therapeutic potential. Curr Opin Investig Drugs 2001, 2: 929-35.
3. Keating, G.M., Goa, K.L. Nesiritide, a review of its use in acute decompensated heart failure. Drugs 2003, 63: 47-70.
4. Burger, A.J., Burger, M.R., Aronson, D. New therapies for the treatment of heart failure. Drugs Today 2002, 38: 31-48.
5. Henry, J.P., Pearce, J.W. The possible role of cardiac stretch receptors in the induction of changes in urine flow. J Physiol 1956, 572-5.
6. Jamieson, J.D., Palade G.E. Specific granules in atrial muscle cells. J Cell Biol 1964, 23: 151-72.
7. Baines, A.D., DeBold, A.J., Sonnenberg, H. Natriuretic effect of atrial extract on isolated perfused rat kidney. Can J Physiol Pharmacol 1983, 61: 1462-6.
8. Sudoh, T., Kangawa, K., Minamino, N. et al. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81.
9. Yasue, H., Obata, K., Okumura, K. et al. Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest 1989, 83: 46-51.
10. Yoshimura, M., Yasue, H., Okumura, K. et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993, 87: 464-9.
11. Cohn, J.N., Levine, T.B., Olivari, M.T. et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311: 819-23.
12. Francis, G.S., Benedict, C., Johnstone, D.E. et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82: 1724-9.
13. Rouleau, J.L., Packe, R.M., Moye, L. et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. J Am Coll Cardiol 1994, 24: 583-91.
14. Francis, G.S., Cohn, J.N., Johnson, G. et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993, 87 (Suppl. 6): VI40-8.
15. Johnson, W., Omland, T., Hall, C. et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for Class IV heart failure. J Am Coll Cardiol 2002, 39: 1623-9.
16. Fonarow, G.C., Stevenson, L.W., Steimle, A.E. et al. Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure. Circulation 1994, 90: 1-488.
17. Mills, R.M. The failing heart and the hemodynamic response to vasodilator therapy. Clin Cardiol 2003, 26: 257-8.
18. Hobbs, R.E., Miller, L.W., Bott-Silverman, C. et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 78: 896-901.
19. Abraham, W.T., Lowes, B.D., Ferguson, D.A. et al. Systemic hemodynamic, neurohormonal and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998, 4: 37-44.
20. Mills, R.M., LeJemtel, T.H., Horton, D.P. et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure. J Am Coll Cardiol 1999, 34: 155-62.
21. Colucci, W.S., Elkayam, U., Horton, D.P. et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated heart failure. N Engl J Med 2000, 343: 246-53.
22. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerine for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002, 287: 1531-40.
23. Burger, A.J., Horton, D.P., LeJemtel, T. et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J 2002, 144: 1102-8.
24. ADHERE 3rd Quarter Report 9/30/02; Scios Inc.
25. Peacock, W.F., Emerman, C.L. Safety and efficacy of nesiritide in the treatment of decompensated heart failure in observation patients - The PROACTION Trial. J Am Coll Cardiol 2003, 41 (6 Suppl. A): 336A.
26. Yancy, C.W., Saltzberg, M., Berkowitz, R. et al. Management of patients with congestive heart failure after hospitalization: Results from the Follow Up Serial Infusion of Nesiritide (FUSION) Trial. J Cardiac Fail 2003, 9 (s): S11.